Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: A phase II global study

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 661-668

  Ou, Sai Hong Ignatius ^a   Ahn, Jin Seok ^b   De Petris, Luigi ^c   Govindan, Ramaswamy ^d   Yang, James Chih Hsin ^e   Hughes, Brett ^f   Lena, Hervé ^g   Moro Sibilot, Denis ^h   Bearz, Alessandra ⁱ   Ramirez, Santiago Viteri ^j   Mekhail, Tarek ^k   Spira, Alexander ^l   Bordogna, Walter ^m   Balas, Bogdana ^m   Morcos, Peter N ^m   Monnet, Annabelle ^m   Zeaiter, Ali ^m   Kim, Dong Wan ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sungkyunkwan University   (South Korea)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g RENNES UNIVERSITY HOSPITAL   (France)

^h GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j INSTITUT UNIVERSITARI DEXEUS   (Spain)

^k FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^l Virginia Cancer Specialists   (United States)

^m F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁿ Seoul National University Hospital   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CRIZOTINIB; CARBAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; GENE REARRANGEMENT; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; VOMITING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; ENZYMOLOGY; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; SECONDARY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CARBAZOLES; CARCINOMA, NON-SMALL-CELL LUNG; CENTRAL NERVOUS SYSTEM NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84964343904     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.9443     Document Type: Article

References (27)

1. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 363:1693-1703, 2010
2. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
3. Kim DW, Ahn MJ, Shi Y, et al: Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small-cell lung cancer. Ann Oncol 23, 2012(suppl; abstr 1230PD)
4. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
5. Solomon BJ, Mok T, Kim DW, et al: PROFILE 1014 Investigators: First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167-2177, 2014
6. Ou SH, Jänne PA, Bartlett CH, et al: Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 25:415-422, 2014
7. Khozin S, Blumenthal GM, Zhang L, et al: FDA approval: Ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 21:2436-2439, 2015
8. Kinoshita K, Asoh K, Furuichi N, et al: Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 20:1271-1280, 2012
9. Sakamoto H, Tsukaguchi T, Hiroshima S, et al: CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679-690, 2011
10. Kodama T, Tsukaguchi T, Yoshida M, et al: Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351:215-221, 2014
11. Kodama T, Tsukaguchi T, Satoh Y, et al: Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Mol Cancer Ther 13:2910-2918, 2014
12. Kodama T, Hasegawa M, Takanashi K, et al: Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74:1023-1028, 2014
13. Gadgeel SM, Gandhi L, Riely GJ, et al: Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119-1128, 2014
14. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
15. Lovly CM, Shaw AT: Molecular pathways: Resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res 20:2249-2256, 2014
16. Camidge DR, Pao W, Sequist LV: Acquired resistance to TKIs in solid tumours: Learning from lung cancer. Nat Rev Clin Oncol 11:473-481, 2014
17. Costa DB, Shaw AT, Ou SH, et al: Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881-1888, 2015
18. Costa DB, Kobayashi S, Pandya SS, et al: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443-e445, 2011
19. Shaw AT, Yeap BY, Solomon BJ, et al: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol 12:1004-1012, 2011
20. Ou SH, Sommers KR, Azada MC, et al: Alectinib induces a durable (.15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist 20:224-226, 2015
21. Gainor JF, Sherman CA, Willoughby K, et al: Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol 10:232-236, 2015
22. Shaw AT, Kim DW, Mehra R, et al: Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370:1189-1197, 2014
23. Shaw AT, Mehra R, Tan D S W, et al: Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study. Ann Oncol 25: iv426-iv470, 2014(suppl 4)
24. Ohe Y, Nishio M, Kiura K, et al: A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): Updated progression-free survival (PFS) and safety results from AF-001JP. J Clin Oncol 33, 2015(suppl; abstr 8061)
25. Ou S, Gadgeel S, Chiappori A, et al: Safety and efficacy analysis of RO5424802/CH5424802 in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients who have failed crizotinib in a dose-finding phase I study (AF-002JG, NCT01588028). Eur J Cancer 2013;49 S(uppl 2): LBA44
26. Seto T, Kiura K, Nishio M, et al: CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-arm, open-label, phase 1-2 study. Lancet Oncol 14:590-598, 2013
27. Malik SM, Maher VE, Bijwaard KE, et al: US Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 20:2029-2034, 2014